Skip to ContentGo to accessibility pageKeyboard shortcuts menu
OpenStax Logo
Pharmacology for Nurses

35.4 Urinary Stimulants

Pharmacology for Nurses35.4 Urinary Stimulants

Learning Outcomes

By the end of this section, you should be able to:

  • 35.4.1 Identify the characteristics of urinary stimulant drugs used for urinary and bladder disorders.
  • 35.4.2 Explain the indications, actions, adverse reactions, contraindications, and interactions of urinary stimulant drugs used for urinary and bladder disorders.
  • 35.4.3 Describe nursing implications of urinary stimulant drugs used for urinary and bladder disorders.
  • 35.4.4 Explain the client education related to urinary stimulant drugs used for urinary and bladder disorders.

Urinary stimulants stimulate the smooth muscles of the urinary bladder. These drugs work by activating the muscarinic receptors of the bladder, leading to increased bladder contractions and improved bladder emptying. They are primarily prescribed for urinary retention or to improve bladder function in individuals with certain neurologic conditions, such as a spinal cord injury.

Bethanechol Chloride

Bethanechol chloride (Duvoid) is indicated for acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention (Padda & Derain, 2022).

Determine the minimum effective dose by giving 5–10 mg initially and repeating the same amount at hourly intervals until a satisfactory response occurs or until a maximum of 50 mg has been given (DailyMed, Bethanechol chloride, 2022).

The drug’s effects sometimes appear within 30 minutes, usually peak between 60 and 90 minutes, and persist for approximately 1 hour (DailyMed, Bethanechol chloride, 2022).

Adverse Effects and Contraindications

Common adverse effects include malaise, urinary urgency, headache, vasomotor response, sweating, and miosis. Contraindications include hyperthyroidism, peptic ulcer disease, asthma, pronounced bradycardia, hypotension, coronary artery disease, seizure, Parkinson’s disease, and hypersensitivity to the drug or any of its components.

Table 35.6 is a drug prototype table for urinary stimulants featuring bethanechol chloride. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

Drug Class
Urinary stimulant, cholinergic

Mechanism of Action
Stimulates activation of the parasympathetic nervous system, causing increased tone of the detrusor muscle of the bladder, producing contraction and emptying of the bladder
Drug Dosage
10–50 mg orally 3–4 times a day.
Indications
Treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention
Neurogenic atony of the urinary bladder with retention

Therapeutic Effects
Minimizes urinary retention
Drug Interactions
Atropine
Diphenhydramine
Donepezil
Glutamine
Hyoscyamine
Neostigmine
Procainamide
Propantheline
Scopolamine

Food Interactions
No significant interactions
Adverse Effects
Malaise
Headache
Urinary urgency
Sweating
Vasomotor response
Miosis
Monitor closely for bacteremia due to reflex infection from incomplete bladder emptying
Contraindications
Hypersensitivity
Hyperthyroidism
Peptic ulcer disease
Asthma
Bradycardia
Hypotension
Coronary artery disease
Seizures
Parkinson’s disease
Table 35.6 Drug Prototype Table: Bethanechol Chloride (source: https://dailymed.nlm.nih.gov/dailymed/)

Nursing Implications

The nurse should do the following for clients who are taking urinary stimulants:

  • Before administering the drug, check the client’s medical history, current drug list (including over-the-counter medications), and allergies.
  • Monitor the client closely for vasomotor responses, such as hypotension, bradycardia, and orthostatic hypotension.
  • For a client taking bethanechol chloride, monitor closely for bronchospasm, wheezing, and tachycardia because these can be serious adverse effects of the drug.
  • Monitor the client’s urine output closely.
  • Provide client teaching regarding the drug and when to call the health care provider. See below for additional client teaching guidelines.

Client Teaching Guidelines

The client taking a urinary stimulant should:

  • Take the medication as prescribed by their health care provider.
  • Take bethanechol chloride on an empty stomach, at least 1 hour before or 2 hours after a meal, for better absorption.
  • Notify their health care provider if symptoms do not improve within 90 minutes after taking bethanechol chloride because the treatment may need to be modified.
  • Store bethanechol chloride at room temperature and away from moisture and heat.
  • Avoid getting up too fast from a sitting or lying position because this drug may cause a vasomotor response that includes dizziness.
The client taking a urinary stimulant should not:
  • Take two or more doses at one time because this may cause a significant vasomotor response such as severe hypotension and bradycardia.
Citation/Attribution

This book may not be used in the training of large language models or otherwise be ingested into large language models or generative AI offerings without OpenStax's permission.

Want to cite, share, or modify this book? This book uses the Creative Commons Attribution License and you must attribute OpenStax.

Attribution information
  • If you are redistributing all or part of this book in a print format, then you must include on every physical page the following attribution:
    Access for free at https://openstax.org/books/pharmacology/pages/1-introduction
  • If you are redistributing all or part of this book in a digital format, then you must include on every digital page view the following attribution:
    Access for free at https://openstax.org/books/pharmacology/pages/1-introduction
Citation information

© May 15, 2024 OpenStax. Textbook content produced by OpenStax is licensed under a Creative Commons Attribution License . The OpenStax name, OpenStax logo, OpenStax book covers, OpenStax CNX name, and OpenStax CNX logo are not subject to the Creative Commons license and may not be reproduced without the prior and express written consent of Rice University.